DexCom (DXCM) vs DENTSPLY SIRONA (XRAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DexCom (DXCM) has outperformed DENTSPLY SIRONA (XRAY) over the past year, gaining 27.7% versus a loss of 30.7%. Over five years, DXCM leads with a -38.1% price change compared with -85.2% for XRAY. DexCom is the larger company by market cap ($31.85 billion vs $1.73 billion), about 18.4 times the size.
On valuation, DENTSPLY SIRONA trades at a lower forward P/E (5.8x vs 27.0x for DexCom). DENTSPLY SIRONA pays a dividend yielding 3.68%, while DexCom does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | XRAY |
|---|---|---|
| Share price | $84.41 | $8.69 |
| Market cap | $31.85B | $1.73B |
| 1-day change | +0.13% | +1.76% |
| YTD return | +27.02% | -25.28% |
| 1-year return | +27.67% | -30.74% |
| 5-year return | -38.07% | -85.24% |
| P/E ratio (TTM) | 33.50 | — |
| Forward P/E | 26.99 | 5.80 |
| EPS (TTM) | $2.52 | $-2.73 |
| Dividend yield | 0.00% | 3.68% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $4.66B | — |
| Revenue growth (YoY) | +15.60% | — |
| Net income (latest FY) | $836.30M | — |
| Gross margin | 60.10% | — |
| Operating margin | 19.56% | — |
| Net margin | 17.94% | — |
| 52-week high | $92.59 | $14.76 |
| 52-week low | $54.11 | $8.38 |
| Distance from 52-week high | -8.83% | -41.12% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +14.00% | +54.20% |
| Average volume | 4.44M | 4.73M |
| Shares outstanding | 377.36M | 199.35M |
| Employees | 11,000 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 18.4 times larger than DENTSPLY SIRONA by market value ($31.85B vs $1.73B).
- DXCM has outperformed XRAY by 58.4 percentage points over the past year.
- DENTSPLY SIRONA offers a meaningfully higher dividend yield (3.68% vs 0.00%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About DENTSPLY SIRONA
XRAY stock →DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.
Health Care · Medical/Dental Instruments · 14,000 employees
DXCM vs XRAY FAQ
Which is bigger, DexCom or DENTSPLY SIRONA?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $1.73B for DENTSPLY SIRONA (XRAY).
Which stock has performed better over the past year, DXCM or XRAY?
DXCM returned +27.67% over the past 12 months, compared with -30.74% for XRAY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, DexCom or DENTSPLY SIRONA?
DENTSPLY SIRONA pays a dividend yielding 3.68%, while DexCom does not currently pay a regular dividend.
Are DexCom and DENTSPLY SIRONA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.